{
  "trial_id": "NCT00830505",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Written informed consent given by patient",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Male or female patients between 18 and 65 years of age inclusive",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Persistent stable asthmatics (FEV1 > 60%)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "On \u2264 1000 \u00b5g FP or equivalent or if on combination therapy up to 500 \u00b5g of FP or equivalent",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients suffering from stable, persistent, mild to moderate asthma as defined by GINA Guidelines and for whom FEV1 > 60 %",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "In the opinion of the investigator, able and willing to comply with the requirements of the protocol",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Severe asthmatics as defined by an FEV1 < 60% or PEF variability >30% or with continual daytime or nocturnal symptoms.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Known or suspected hypersensitivity to FP or any other constituents of the Test or Reference pMDI",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of asthma and is currently using inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg. He does not have any severe asthmatic symptoms or known hypersensitivity to FP.",
  "_meta": {
    "topic_id": "23",
    "trial_id": "NCT00830505",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}